਀㰀栀琀洀氀㸀 ਀㰀氀椀渀欀 爀攀氀㴀∀猀琀礀氀攀猀栀攀攀琀∀ 琀礀瀀攀㴀∀琀攀砀琀⼀挀猀猀∀ 栀爀攀昀㴀∀猀琀礀氀攀⸀挀猀猀∀⼀㸀 ਀㰀戀漀搀礀㸀

Centre de Référence des Rhumatismes Inflammatoires et Maladies Autoimmunes Systémiques Rares de l’Enfant (RAISE) / 2017

61

Giannini

E,

Childhood

Arthritis

and

Rheumatology

Alliance,

Research

Pediatric

International

Rheumatology
Trials

Organization,

Pediatric

Collaborative

Rheumatology
Study Group. Preliminary criteria
for

clinical

remission

for

select

categories

of

juvenile

idiopathic

arthritis.

J

Rheumatol.

Nov;31(11):2290–4.

2004

Évolution

Lomater C, Gerloni V, Gattinara
M,

Mazzotti J, Cimaz R, Fantini

F.

Systemic

idiopathic
retrospective

onset

juvenile

arthritis:

a

80

study

of

consecutive patients followed for
10

years.

J

Rheumatol.

2000

Feb;27(2):491–6.

Ravelli

A,

Martini

A.

Early

predictors of outcome in juvenile

idiopathic

arthritis.

Clin

Exp

Oct;21(5

Rheumatol.

2003

Suppl 31):S89-93.

Singh-Grewal

D,

Schneider

R,

Bayer

N,

Feldman

Predictors

BM.

course

systemic

arthritis:

of

disease

and

remission

in

idiopathic

juvenile
significance of early clinical and

laboratory

features.

Arthritis

Rheum.

2006

May;54(5):1595–

601.

Wallace CA, Huang B, Bandeira

M,

Ravelli

A,

Giannini

EH.

Patterns

of

clinical

remission

in

select

categories

of

arthritis.

juvenile
Arthritis

idiopathic
Rheum. 2005 Nov;52(11):3554–
62.

Formes systémiques d’AJI

De

Benedetti

F,

Brunner

HI,

Ruperto

N,

Kenwright

A,

Wright

S,

Calvo

I,

et

al.

Randomized
tocilizumab

trial

of

systemic

in

juvenile

idiopathic

arthritis.

N

Dec

Engl

J

Med.

2012

20;367(25):2385–95.

Kimura

Y,

Weiss

JE,

Haroldson KL, Lee T, Punaro

M,

Oliveira

S,

et

al.

Pulmonary

hypertension

and

other

potentially

fatal

pulmonary

complications

in

systemic

juvenile

idiopathic

arthritis.

Arthritis

Care

Res

(Hoboken).
May;65(5):745–52.

2013

Lovell

DJ,

Giannini

EH,

Reiff

AO, Kimura Y, Li S, Hashkes
PJ,

et

al.

Long-term

safety

and

efficacy

of

rilonacept

in

patients

with

juvenile

systemic

arthritis.

2013

idiopathic

Arthritis

Rheum.

Sep;65(9):2486–96.

Nigrovic
Prince

PA,

Mannion

M,

A,

FHM,

Zeft

Rabinovich

CE,

van

Rossum

MAJ, et al. Anakinra as first-

line

disease-modifying

therapy

in

systemic

juvenile

idiopathic

arthritis:

report

of

forty-six

patients

international

from

an

multicenter

series. Arthritis Rheum. 2011
Feb;63(2):545–55.

Quartier P, Allantaz F, Cimaz

R,

Pillet

P,

Messiaen

C,

Bardin C, et al. A multicentre,

randomised,

double-blind,

placebo-controlled

trial

with

the

interleukin-1

receptor

antagonist

anakinra

in

patients

with

systemic-onset

਀㰀⼀栀琀洀氀㸀